HDAC5 Promotes Osteosarcoma Progression by Upregulation of Twist 1 Expression

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2013 Oct 5

PMID 24092570

Citations 11

Authors

Jie Chen

Jun Xia

Yong-Lin Yu

Si-Qun Wang

Yi-Bing Wei

Fei-Yan Chen

Gang-Yong Huang

Jing-Sheng Shi

Affiliations

Soon will be listed here.

Abstract

Histone deacetylases (HDACs) form a family of enzymes, which have fundamental roles in the epigenetic regulation of gene expression and contribute to the growth, differentiation, and apoptosis of cancer cells. In this study, we firstly investigated the biological function of HDAC5 in osteosarcoma cells. We found that mRNA and protein levels of HDAC5 were upregulated in osteosarcoma tissues and cell lines. Furthermore, overexpression of HDAC5 could promote cell proliferation in osteosarcoma cell lines. In contrast, HDAC5 knockdown using small interfering RNA inhibited cell proliferation. At the molecular level, we demonstrated that HDAC5 promoted mRNA expression of twist 1, which has been reported as an oncogene. Together, these results highlighted for the first time an unrecognized link between HDAC5 and osteosarcoma progression and demonstrated that its specific inhibition might contribute to the treatment of tumorigenesis.

Citing Articles

Decoding the Impact of Tumor Microenvironment in Osteosarcoma Progression and Metastasis.

Nirala B, Yamamichi T, Petrescu D, Shafin T, Yustein J Cancers (Basel). 2023; 15(20).

PMID: 37894474 PMC: 10605493. DOI: 10.3390/cancers15205108.

promotes lung adenocarcinoma progression by upregulating histone deacetylase 5.

Shen J, Ni Y, Guan Q, Li R, Cao H, Geng Y Front Microbiol. 2023; 14:1121863.

PMID: 36819033 PMC: 9929947. DOI: 10.3389/fmicb.2023.1121863.

Twist1 as a target for prevention of cutaneous squamous cell carcinoma.

Wang T, Rho O, Eguiarte-Solomon F, DiGiovanni J Mol Carcinog. 2022; 62(1):62-76.

PMID: 36373194 PMC: 9772054. DOI: 10.1002/mc.23482.

Proteomic and transcriptomic profiles of human urothelial cancer cells with histone deacetylase 5 overexpression.

Vasudevan A, Hoffmann M, Poschmann G, Petzsch P, Wiek C, Stuhler K Sci Data. 2022; 9(1):240.

PMID: 35624179 PMC: 9142574. DOI: 10.1038/s41597-022-01319-0.

METTL3 stabilizes HDAC5 mRNA in an mA-dependent manner to facilitate malignant proliferation of osteosarcoma cells.

Jiang R, Dai Z, Wu J, Ji S, Sun Y, Yang W Cell Death Discov. 2022; 8(1):179.

PMID: 35396379 PMC: 8993827. DOI: 10.1038/s41420-022-00926-5.

References

Klein M, Siegal G . Osteosarcoma: anatomic and histologic variants. Am J Clin Pathol. 2006; 125(4):555-81. DOI: 10.1309/UC6K-QHLD-9LV2-KENN. View

Lahm A, Paolini C, Pallaoro M, Nardi M, Jones P, Neddermann P . Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci U S A. 2007; 104(44):17335-40. PMC: 2077257. DOI: 10.1073/pnas.0706487104. View

Qin L, Liu Z, Chen H, Xu J . The steroid receptor coactivator-1 regulates twist expression and promotes breast cancer metastasis. Cancer Res. 2009; 69(9):3819-27. PMC: 2911143. DOI: 10.1158/0008-5472.CAN-08-4389. View

Mahlknecht U, Schnittger S, Ottmann O, Schoch C, Mosebach M, Hiddemann W . Chromosomal organization and localization of the human histone deacetylase 5 gene (HDAC5). Biochim Biophys Acta. 2000; 1493(3):342-8. DOI: 10.1016/s0167-4781(00)00191-3. View

Vigushin D, Coombes R . Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs. 2002; 13(1):1-13. DOI: 10.1097/00001813-200201000-00001. View

Zhang C, McKinsey T, Chang S, Antos C, Hill J, Olson E . Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell. 2002; 110(4):479-88. PMC: 4459650. DOI: 10.1016/s0092-8674(02)00861-9. View

Weiss M, Abel E, Mayberry M, Basile K, Berger A, Aplin A . TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells. Cancer Res. 2012; 72(24):6382-92. PMC: 3531871. DOI: 10.1158/0008-5472.CAN-12-1033. View

Tofilon P, Camphausen K . HDAC inhibitors in cancer care. Oncology (Williston Park). 2010; 24(2):180-5. PMC: 8473946. View

Ansieau S, Bastid J, Doreau A, Morel A, Bouchet B, Thomas C . Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell. 2008; 14(1):79-89. DOI: 10.1016/j.ccr.2008.06.005. View

10.

McKinsey T, Zhang C, Lu J, Olson E . Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature. 2000; 408(6808):106-11. PMC: 4459600. DOI: 10.1038/35040593. View

11.

Milde T, Oehme I, Korshunov A, Kopp-Schneider A, Remke M, Northcott P . HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. Clin Cancer Res. 2010; 16(12):3240-52. DOI: 10.1158/1078-0432.CCR-10-0395. View

12.

Kao H, Downes M, Ordentlich P, Evans R . Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. Genes Dev. 2000; 14(1):55-66. PMC: 316336. View

13.

Roy S, Shor A, Bagui T, Seto E, Pledger W . Histone deacetylase 5 represses the transcription of cyclin D3. J Cell Biochem. 2008; 104(6):2143-54. DOI: 10.1002/jcb.21771. View

14.

Song S, Han S, Bang Y . Epigenetic-based therapies in cancer: progress to date. Drugs. 2011; 71(18):2391-403. DOI: 10.2165/11596690-000000000-00000. View

15.

Eppert K, Wunder J, Aneliunas V, Kandel R, Andrulis I . von Willebrand factor expression in osteosarcoma metastasis. Mod Pathol. 2004; 18(3):388-97. DOI: 10.1038/modpathol.3800265. View

16.

Tan M, Choong P, Dass C . Osteosarcoma: Conventional treatment vs. gene therapy. Cancer Biol Ther. 2008; 8(2):106-17. DOI: 10.4161/cbt.8.2.7385. View

17.

Casas E, Kim J, Bendesky A, Ohno-Machado L, Wolfe C, Yang J . Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis. Cancer Res. 2011; 71(1):245-54. PMC: 3025803. DOI: 10.1158/0008-5472.CAN-10-2330. View

18.

Shiota M, Izumi H, Onitsuka T, Miyamoto N, Kashiwagi E, Kidani A . Twist promotes tumor cell growth through YB-1 expression. Cancer Res. 2008; 68(1):98-105. DOI: 10.1158/0008-5472.CAN-07-2981. View

19.

Bolden J, Peart M, Johnstone R . Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5(9):769-84. DOI: 10.1038/nrd2133. View

20.

Khan O, La Thangue N . HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol. 2011; 90(1):85-94. DOI: 10.1038/icb.2011.100. View